线粒体代谢作为髓系白血病的潜在治疗靶点
综述探讨髓系白血病细胞代谢重编程,重点分析氧化磷酸化(OXPHOS)在白血病干细胞(LSCs)和耐药细胞中的作用,汇总靶向该过程的现有药物,指出识别能量代谢依赖可为开发更精准治疗策略提供方向。
要点
- LSCs和耐药细胞依赖线粒体OXPHOS,对OXPHOS抑制敏感。
- 代谢适应是白血病治疗耐药和复发的机制之一。
- 靶向异常能量代谢是开发髓系白血病新疗法的 relevant 策略。
核心结论
- 白血病干细胞和耐药细胞依赖线粒体氧化磷酸化,靶向该代谢通路是髓系白血病的潜在治疗策略。
研究设计与样本
- 综述,汇总近期关于白血病细胞代谢重编程及靶向OXPHOS药物的实验研究证据。
主要发现
- LSCs和耐药细胞依赖线粒体代谢,对OXPHOS抑制敏感。
- 代谢适应是治疗耐药和疾病复发的贡献机制之一。
临床怎么用
- 识别特定能量代谢依赖有助于指导髓系白血病新靶向治疗策略的开发。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
While the understanding of the genomic aberrations that underpin chronic and acute myeloid leukaemia (CML and AML) has allowed the development of therapies for these diseases, limitations remain. These become apparent when looking at the frequency of treatment resistance leading to disease relapse in leukaemia patients. Key questions regarding the fundamental biology of the leukaemic cells, such as their metabolic dependencies, are still unresolved. Even though a majority of leukaemic cells are killed during initial treatment, persistent leukaemic stem cells (LSCs) and therapy-resistant cells are still not eradicated with current treatments, due to various mechanisms that may contribute to therapy resistance, including cellular metabolic adaptations. In fact, recent studies have shown that LSCs and treatment-resistant cells are dependent on mitochondrial metabolism, hence rendering them sensitive to inhibition of mitochondrial oxidative phosphorylation (OXPHOS). As a result, rewired energy metabolism in leukaemic cells is now considered an attractive therapeutic target and the significance of this process is increasingly being recognised in various haematological malignancies. Therefore, identifying and targeting aberrant metabolism in drug-resistant leukaemic cells is an imperative and a relevant strategy for the development of new therapeutic options in leukaemia. In this review, we present a detailed overview of the most recent studies that present experimental evidence on how leukaemic cells can metabolically rewire, more specifically the importance of OXPHOS in LSCs and treatment-resistant cells, and the current drugs available to target this process. We highlight that uncovering specific energy metabolism dependencies will guide the identification of new and more targeted therapeutic strategies for myeloid leukaemia.
引用
- de Beauchamp L, Himonas E, Helgason GV, et al. Mitochondrial metabolism as a potential therapeutic target in myeloid leukaemia. Leukemia. 2021. PMID: 34561557. doi:10.1038/s41375-021-01416-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。